# Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

> **NCT07551596** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (estimated)

## Conditions studied

- Colorectal Adenocarcinoma
- Stage II Colorectal Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Balstilimab
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Botensilimab
- **PROCEDURE:** Radiographic Examination

## Key facts

- **NCT ID:** NCT07551596
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-14
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07551596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07551596, "Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT07551596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*